

The SEVOrane^{AF} team from AbbVie AT YOUR SIDE FOR OVER 20 YEARS[†]



Over 935 million patient exposures worldwide.¹

SEVOrane^{AF} (sevoflurane) is indicated for: induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Consult the Product Monograph at abbvie.ca/content/dam/abbviecorp/ca/english/docs/SEVORANE_PM_EN.pdf for important information on contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use.²

[†] SEVOrane^{AF} was launched in Canada in 1995.

References: 1. Data on file. AbbVie Corporation. April 19, 2017. 2. SEVOrane^{AF} (sevoflurane) Product Monograph AbbVie Corporation. December 23, 2014.

SEVOrane^{AF} is a registered trademark of AbbVie Corporation.

AbbVie Corporation
Saint-Laurent, Québec H4S 1Z1
Printed in Canada. SEV2054A – May 2017